AstraZeneca plc vs VanEck Gold Miners ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while VanEck Gold Miners ETF trades at $91.09. The key difference: AstraZeneca plc pays a 2.01% dividend while VanEck Gold Miners ETF pays none, and VanEck Gold Miners ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | GDX | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $115.84 |
52-Week Low | $147.06 | $56.60 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
GDX (VanEck Gold Miners ETF) trades at $90.96, up 0.52% with a bullish technical signal from moving averages but overbought RSI readings. The ETF benefits from gold's seven-week rally to near $4,300/oz, though mining stocks have lagged the metal's gains. Recent institutional activity shows mixed sentiment with City Holding reducing its position by 85.8% while Axiom Investment added a $934,000 stake in Q1 2026.
Gold miners offer leveraged exposure to rising gold prices with attractive valuations, but face volatility risks. The sector's free cash flow yields are at record highs, supporting potential upside if gold sustains momentum. Key risks include gold price sensitivity, mining operational challenges, and competition from physical gold ETFs with lower expense ratios.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →